Literature DB >> 14563634

Pharmacologically regulated Fas-mediated death of adoptively transferred T cells in a nonhuman primate model.

Carolina Berger1, C Anthony Blau, Meei-Li Huang, John D Iuliucci, David C Dalgarno, Joëlle Gaschet, Shelly Heimfeld, Tim Clackson, Stanley R Riddell.   

Abstract

Conditional suicide genes derived from pathogens have been developed to confer drug sensitivity and enhance safety of cell therapy, but this approach is limited by immune responses to the transgene product. We examined a strategy to regulate survival of transferred cells based on induction of apoptosis through oligomerization of a modified human Fas receptor by a bivalent drug (AP1903). Three macaques (Macaca nemestrina) received autologous T cells retrovirally engineered to express a Fas suicide-construct (LV'VFas). High levels of transduced cells were present in blood following cell transfer, but LV'VFas(+) cells declined rapidly after AP1903 administration. A small fraction of LV'VFas(+) cells resisted elimination by AP1903, in part due to insufficient levels of transgene expression in resting T cells, because reactivation of these cells in vitro enhanced sensitivity to AP1903. An immune response to the transgene product was observed, but epitope mapping indicated the response was directed to discrete components of human LV'VFas that were variant with the corresponding macaque sequences. These data demonstrate that chemically induced dimerization can be used to regulate survival of adoptively transferred T cells in vivo.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14563634     DOI: 10.1182/blood-2003-08-2908

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  17 in total

1.  An inducible caspase 9 safety switch for T-cell therapy.

Authors:  Karin C Straathof; Martin A Pulè; Patricia Yotnda; Gianpietro Dotti; Elio F Vanin; Malcolm K Brenner; Helen E Heslop; David M Spencer; Cliona M Rooney
Journal:  Blood       Date:  2005-02-22       Impact factor: 22.113

2.  A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR.

Authors:  Hiroki Torikai; Andreas Reik; Pei-Qi Liu; Yuanyue Zhou; Ling Zhang; Sourindra Maiti; Helen Huls; Jeffrey C Miller; Partow Kebriaei; Brian Rabinovich; Brian Rabinovitch; Dean A Lee; Richard E Champlin; Chiara Bonini; Luigi Naldini; Edward J Rebar; Philip D Gregory; Michael C Holmes; Laurence J N Cooper
Journal:  Blood       Date:  2012-04-24       Impact factor: 22.113

3.  Redirection of T cells by delivering a transgenic mouse-derived MDM2 tumor antigen-specific TCR and its humanized derivative is governed by the CD8 coreceptor and affects natural human TCR expression.

Authors:  Ralf-Holger Voss; Jürgen Kuball; Renate Engel; Philippe Guillaume; Pedro Romero; Christoph Huber; Matthias Theobald
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

4.  A non-human primate model for analysis of safety, persistence, and function of adoptively transferred T cells.

Authors:  C Berger; M Berger; D Anderson; S R Riddell
Journal:  J Med Primatol       Date:  2010-11-02       Impact factor: 0.667

5.  Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation.

Authors:  Carolina Berger; Mary E Flowers; Edus H Warren; Stanley R Riddell
Journal:  Blood       Date:  2005-11-10       Impact factor: 22.113

Review 6.  NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies.

Authors:  Edwin P Alyea; Daniel J DeAngelo; Jeffrey Moldrem; John M Pagel; Donna Przepiorka; Michel Sadelin; James W Young; Sergio Giralt; Michael Bishop; Stan Riddell
Journal:  Biol Blood Marrow Transplant       Date:  2010-05-24       Impact factor: 5.742

7.  Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia.

Authors:  Paulina J Paszkiewicz; Simon P Fräßle; Shivani Srivastava; Daniel Sommermeyer; Michael Hudecek; Ingo Drexler; Michel Sadelain; Lingfeng Liu; Michael C Jensen; Stanley R Riddell; Dirk H Busch
Journal:  J Clin Invest       Date:  2016-10-17       Impact factor: 14.808

Review 8.  Adoptive T-cell therapy for B-cell malignancies.

Authors:  Michael Hudecek; Larry D Anderson; Tetsuya Nishida; Stanley R Riddell
Journal:  Expert Rev Hematol       Date:  2009-10       Impact factor: 2.929

9.  Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates.

Authors:  Carolina Berger; Michael C Jensen; Peter M Lansdorp; Mike Gough; Carole Elliott; Stanley R Riddell
Journal:  J Clin Invest       Date:  2008-01       Impact factor: 14.808

Review 10.  Immunotherapy in acute leukemia.

Authors:  Wing Leung
Journal:  Semin Hematol       Date:  2009-01       Impact factor: 3.851

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.